Prostate Cancer Coverage from Every Angle
Advertisement
Advertisement

Recent News

Pain Response With Different Therapies for Castration-Resistant Prostate Cancer
TAT 2020: IL-18 and Anticancer Immunity in Prostate Cancer
TAT 2020: CAR-Targeting L1CAM in Neuroendocrine Prostate Cancer
Combination Therapy for Enzalutamide-Resistant Prostate Cancer
GU Cancers Symposium 2020: Quality of Life in Men Treated for Advanced Prostate Cancer
GU Cancers Symposium 2020: Prostate Cancer Subtypes as Predictive Biomarker for Response to Chemotherapy
Fox Chase Researcher Receives Grant to Study Role of Cholesterol in Resistance to Prostate Cancer Treatment
GU Cancers Symposium 2020: Apalutamide and Time to Second Progression in Patients With Prostate Cancer
GU Cancers Symposium 2020: Use of Novel PET/CT Radiotracer in Staging High-Risk Prostate Cancer
GU Cancers Symposium 2020: Long-Term Outcomes With Hypofractionated Radiotherapy for Prostate Cancer
Using Individualized Pelvic Physical Therapy to Improve Surgical Complications
NCI-MATCH Study: Next Phase for Nivolumab Beyond Colorectal Cancer
Androgen-Deprivation Therapy and Cardiovascular Events in Men With Prostate Cancer
Priority Review Granted by FDA to Olaparib in Castration-Resistant Prostate Cancer
Treatment Trends in Prostate Cancer at MD Anderson Versus Nationwide
At-Home Urine Collection as a Diagnostic Tool for Prostate Cancer
MRI-Guided Ultrasound Technique for Localized Prostate Cancer
FDA Approves Enzalutamide for Metastatic Castration-Sensitive Prostate Cancer
Hemigland Cryoablation for Localized Prostate Cancer: Outcomes at 5 Years
Exercise and Treatment-Related Toxicity to Be Studied in Men With Advanced Prostate Cancer
Is There an Association Between Antidiabetic Medication and Prostate Cancer?
Update on Survival Outcomes With Long-Term Docetaxel in Metastatic Prostate Cancer
Cabazitaxel or Androgen Receptor–Targeted Therapies for Metastatic Prostate Cancer
Noninvasive Blood Test May Improve Accuracy in Detecting Prostate Cancer
In-House Specialty Pharmacy and Cost of Therapies for Prostate Cancer
ESMO 2019: CHEIRON Update on Enzalutamide Plus Docetaxel in Castration-Resistant Prostate Cancer
Pilot Program Focuses on Improving Prostate Cancer Staging Data Entries
Prostate Cancer Foundation Announces Collaborative Research Grants Program
Niraparib Granted Breakthrough Therapy Designation in Metastatic Castration-Resistant Prostate Cancer
ESMO 2019: Does Olaparib Benefit Men With Advanced Castration-Resistant Prostate Cancer?
ASTRO 2019: SABR Versus Observation for Men With Oligometastatic Prostate Cancer


By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.